J. B. Chemicals & Pharmaceuticals has informed that the Company is in receipt of the Establishment Inspection Report (EIR) from the US FDA for the Company's newly set up and commissioned solid oral dosage forms formulations manufacturing facility at Panoli, Gujarat. The US FDA issues an EIR to the Company when an inspection is satisfactorily ‘closed’. The said inspection was carried out from 24th June to 28th June 2019. At the end of the inspection, ‘No Objectionable Observation’ was found and no Form 483 was issued. This new facility known as (T20) has already been approved by the other regulatory authorities like EU, TGA-Australia, Saphra-South Africa. This is another facility in addition to one already approved by US FDA. The new facility will augment the Company's manufacturing capacity for regulated markets like USA, EU, Australia and South Africa.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: